Md. Rakibul Islam
Immunotherapeutics & Biotechnology
 |
|
Biography
Md. Rakibul Islam completed his Bachelor of Pharmacy (BPharm) degree from East West University, Dhaka, Bangladesh in 2012, and his Master of Pharmacy (MPharm) degree in Pharmaceutical Technology and Biopharmaceutics from North South University, Dhaka, Bangladesh in 2015. He has five years of experience working in research and development and in quality operations units with top FDA- and MHRA-approved pharmaceutical companies of Bangladesh, including Square Pharmaceuticals Ltd., Beximco Pharmaceuticals Ltd. (aka Beximco Pharma), and Renata Limited (formerly Pfizer Laboratories). He joined the Graduate Program in Pharmaceutical Sciences as a Doctor of Philosophy (PhD) student in August of 2019, and is presently working in the laboratory of Dr. Irene La-Beck with the Department of Immunotherapeutics and Biotechnology in Abilene.
Education:
- MPharm: North South University, Dhaka, Bangladesh, 2015
- BPharm: East West University, Dhaka, Bangladesh, 2012
Research Interests:
Rakibul is currently working to develop an effective formulation to conjugate a single-chain antibody to a medicated liposomal delivery system that can help ameliorate metastatic tumors. He is involved in developing characterization methods, a method for the conjugation itself, and also for its subsequent in-vitro and in-vivo tests. Since the advent of COVID-19, he has also been working on a project which was envisioned by his mentor and which is focused on determining potential immunological and diseased biomarkers in severely ill patients who are affected by the SARS-CoV2 virus.
Publications
- Md Rakibul Islam, Jalpa Patel, Patricia Ines Back, Hilary Shmeeda, Konstantin Adamsky, Hui Yang, Carlos Alvarez, Alberto A Gabizon, Ninh M La-Beck. Impact of liposomal drug delivery and alendronate co-encapsulation on the immune modulatory effects of doxorubicin in the tumor microenvironment [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022; 10(12 Suppl):Abstract nr A42.
- Islam MR, Patel J, Back PI, Shmeeda H, Adamsky K, Yang H, Alvarez C, Gabizon AA, La-Beck NM. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model. Nanotheranostics. 2022 Sep 1; 6(4):451-464.
- La-Beck NM, Islam MR, Markiewski MM. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine. Front Immunol. 2021 Jan 8;11:603039.
Presentations:
- Md. Rakibul Islam, Jalpa Patel, Patricia Ines Back, Hilary Schmeeda, Konstantin Adamsky, Hui Yang, Carlos Alvarez, Alberto A. Gabizon, Ninh M. La-Beck. "Impact of Liposomal Drug Delivery and Alendronate Co-Encapsulation on the Immune Modulatory Effects of Doxorubicin in the Tumor Microenvironment". American Association for Cancer Research (AACR) Special Conference: Tumor Immunology & Immunotherapy, Boston, MA; October 2022.
- Md. Rakibul Islam, Jalpa Patel, Patricia Ines Back, Hilary Schmeeda, Konstantin Adamsky, Hui Yang, Carlos Alvarez, Alberto A. Gabizon, Ninh M. La-Beck. "Impact of Liposomal Drug Delivery and Alendronate Co-encapsulation on the Immune Modulatory Effects of Doxorubicin in the Tumor Microenvironment". 19th Annual Research Days, TTUHSC Jerry H Hodge School of Pharmacy, Office of Sciences in Amarillo, event at Lubbock, TX; June 2022.
- Md. Rakibul Islam, Patricia Back, Jalpa Patel, Hilary Shmeeda, Savanna Stevens, Alberto A. Gabizon, Ninh M. La-Beck. "Targeting Immunosuppression: Impact of Co-Encapsulated Alendronate-Doxorubicin Liposomes on Tumor Immunologic Milieu". Student Research Week, TTUHSC Graduate School of Biomedical Sciences, Lubbock; March 2022.
- Oral Presentation (Junior Graduate Presentations): Md. Rakibul Islam, Jalpa Patel, Hilary Shmeeda, Claire Shudde, Rajareddy Kallem, Indhumathy Subramaniyana, Vindhya Edpuganti, Robin Rajan, William C. Putnam, Alberto A. Gabizon, Ninh M. La-Beck. "Combination of Immune Checkpoint Inhibitor and Alendronate for the Treatment of Melanoma". Research Days, Office of Sciences, TTUHSC Jerry H Hodge School of Pharmacy, Amarillo (virtual); June 2021.
Seminars:
- 12/02/2022 "Impact of nanoparticle-mediated drug delivery and co-encapsulation of alendronate on the immune modulatory effects of doxorubicin in the tumor microenvironment"
- 10/08/2021 "Overcoming Antineoplastic Drug Resistance in Triple-Negative Breast Cancer" [Oral Qualifying Exam, public presentation counted as Seminar credit]
- 04/23/2021 "Combination of Immune Checkpoint Inhibitor and Alendronate for the Treatment of Melanoma"
Awards/Scholarships:
Before Admission to GPPS:
- Merit Scholarship, North South University, Dhaka, Bangladesh, 2013.
After Admission to GPPS:
- Mary Lou Clements-Mann Scholarship, TTUHSC Graduate School of Biomedical Sciences, Fall 2020.
Memberships:
- American Association for Cancer Research (AACR), 2022-present.
- Immunotherapeutics and Biotechnology Graduate Student Association (IBGSA) – President, 2022-2023.
- Immunotherapeutics and Biotechnology Graduate Student Association (IBGSA) – Secretary, 2021-2022.
- Immunotherapeutics and Biotechnology Graduate Student Association (IBGSA), 2019-present.